Skip to content

Study · Observational study · n = 110 · 2015

1 result

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls.

Shiasi Arani K, Heidari F

International journal of endocrinology and metabolism1 Jul 2015Cited by 21 (Europe PMC)

PMID26401141 (opens in a new tab)PMCIDPMC4577733 (opens in a new tab)DOI10.5812/ijem.23085v2 (opens in a new tab)PepBankPUB-26401141
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studySafety outcome

    In girls with precocious puberty, obesity prevalence did not significantly differ between triptorelin-treated and untreated groups at follow-up.

    In plain wordsGirls receiving triptorelin had similar obesity prevalence to untreated girls at follow-up.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeObesity prevalence
    Study

    n = 110

    Comparator
    Untreated girls with slowly progressive precocious puberty
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    The prevalence of obesity was not significantly different between study groups at baseline and at and sixth and 12th months of therapy (P = 0.11, P = 0.068, and P = 0.052, respectively).
    3 context sentences
    Summary · context
    The GnRHa (Triptorelin) was administered intramuscularly for patients with rapidly progressive forms of CPP.
    Summary · context
    Patients with slowly progressive forms of CPP were considered as control group.
    Summary · context
    From 110 subjects with CPP, 46 girls (41.8%) were considered as intervention and 64 (58.2%) as control groups.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.